Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.
about
Pharmacogenetics and anaesthesia: the value of genetic profilingWarfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Applied pharmacogenomics in cardiovascular medicinePharmacogenetics in Jewish populations.Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humansCYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.PharmGKB summary: very important pharmacogene information for CYP4F2Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population.Warfarin dosage response related pharmacogenetics in Chinese population.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population.Association of genetic polymorphisms with warfarin dose requirements in Chinese patients.Pharmacogenetics guided anticoagulation.The pharmacogenetics of the response to warfarin in Chinese.Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients.Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations.Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel.Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.Demographic history and human genetic diversity: pharmacogenomic implications.Automation of diagnostic genetic testing: mutation detection by cyclic minisequencing.Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.Pharmacogenomics Aspect of Warfarin TherapyPharmacogenomics, ancestry and clinical decision making for global populationsLetter to the Editor: Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and BraziliansFrequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian OriginInfluence of proton pump inhibitors andVKORC1mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study
P2860
Q26859221-68E1CD41-1BC9-42C7-9687-5116111C6399Q31131437-CF8CA3C1-6186-48BD-958A-5E7AD27A7366Q33846255-1B85ADC9-EC96-4F84-9DBF-D6ED48D3F46EQ34458720-0C5A3FF9-B57E-4463-A132-7ADEF78EF05EQ34534993-7AB19371-D901-4CDA-B3F4-6BB6F4FCBC41Q34552473-61971B5B-617F-4D68-BFF5-0F1831DD7093Q34664072-33A7EC73-74AD-4017-BADD-F1025C516C8BQ34778035-E0CC18F0-0518-4A94-BB83-3A64B36D89BDQ34977531-8A748A79-9724-4CA2-8149-1BA81A7038D0Q36094919-B33EB238-4AB5-42B4-B726-BD9C6134868BQ37322343-20EEFA1F-EBE4-4020-B3F6-FC3A54B77617Q37398193-FF9489CB-2FE4-472E-912B-A5C362917975Q37808224-552FD722-D415-4940-8631-82129FCA8011Q37948863-4AAF1EA2-04CE-4AD6-87A0-6E4F1E2E757FQ37954183-CDAAA3F6-2A6A-4993-A04E-63FE5A8457F9Q39262868-9C9694D1-6069-4D7B-B6A9-EAE6C0090FDBQ39537454-E2537A6B-B05D-4743-84AA-12220E6817DAQ39732661-A9DD0861-F553-44CF-8583-BEE3E42DE54FQ40480835-1B0F591A-4EB8-43F7-A862-6EC756525B6FQ42335970-C9AF1855-A40D-43C2-9E14-CE67D79E2031Q42722817-8DE7104E-45CE-418E-BDAA-DF9FC2434732Q43097393-0AF98707-C12B-40A0-A857-CF54158EA5D4Q43879115-C348F9C5-174C-4B8A-9158-A41211835826Q44498037-F2A2FE6B-19C3-4993-B748-DA165AC3E612Q47669596-6DBFB797-65FE-4A28-BFDE-6F36B684CDAEQ50140048-DA91A976-0A10-4859-A183-AF716511CF0EQ51743967-179C8142-D3A5-4F43-B608-D244D624D866Q54092302-C3577019-CE83-4C18-BD2E-A1EF69D72193Q57179825-7C51324F-CF7A-4164-89F5-F6754B7DD2DAQ57278395-EF98ABA1-6FAF-4543-9DD5-7BAB9B82D637Q57749449-14D8C80A-B6B4-4CD0-8B83-9B2FDEDBBD12Q57794673-19DC6E4C-55A1-4F3A-9454-797FDC6B8509Q58955464-0F42EC9C-7BF3-4EF5-BAB1-BF25F958AA46
P2860
Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Worldwide allele frequency dis ...... th warfarin dose requirements.
@en
Worldwide allele frequency dis ...... th warfarin dose requirements.
@nl
type
label
Worldwide allele frequency dis ...... th warfarin dose requirements.
@en
Worldwide allele frequency dis ...... th warfarin dose requirements.
@nl
prefLabel
Worldwide allele frequency dis ...... th warfarin dose requirements.
@en
Worldwide allele frequency dis ...... th warfarin dose requirements.
@nl
P2093
P2860
P356
P1476
Worldwide allele frequency dis ...... ith warfarin dose requirements
@en
P2093
Abbigail W Bigham
Agnes Gozdzik
Kendra A Ross
Melissa Edwards
P2860
P2888
P304
P356
10.1038/JHG.2010.73
P577
2010-06-17T00:00:00Z